- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02975752
EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA (EGFRdelEx19)
Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lymph Node Metastases From Patients With Lung Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
First-line treatment with afatinib prolongs overall survival in patients with metastatic non-small-cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations. Conversely, somatic KRAS mutations are negative predictors for benefit from EGFR-targeting agents. Rapid availability of these biomarker results is mandatory to prevent delayed or inferior treatments.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is well-established for lung cancer diagnosis and staging. Next generation sequencing (NGS) via targeted resequencing allows simultaneous interrogation for multiple mutations, but has its limitations based on the amount of tumor tissue required and assay times. RT-PCR using Light-Cycler technology (LC-RTPCR) is a rapid and sensitive assay to detect somatic mutations in various tissues from NSCLC patients. The study's aim was to analyze if LC-RTPCR is feasible for rapid EGFRdelEx19 and KRAS Exon 2 mutation detection in EBUS-TBNA samples and to compare results with results obtained via standard NGS mutation analyses.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- lung adenocarcinoma positive EBUS-TBNA specimen
Exclusion Criteria:
- other diagnosis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
detection of mutations
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Filiz Özkan, MD, Department of Interventional Pneumology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EGFRdelEx 19 KRAS Exon 2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Adenocarcinoma Metastatic
-
AIO-Studien-gGmbHAstraZeneca; CelgeneCompletedCarcinoma, Non-Small-Cell Lung | Non Small Cell Lung Cancer | Metastatic Lung Cancer | Lung Adenocarcinoma Metastatic | Large Cell Lung Carcinoma MetastaticGermany
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedFostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC (FORCE)Metastatic Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma,Non-Small-Cell Lung | Lung Adenocarcinoma Metastatic | Large Cell Lung Carcinoma MetastaticGermany
-
Chinese PLA General HospitalUnknown
-
Groupe Hospitalier Paris Saint JosephWithdrawnMetastatic Lung Adenocarcinomas
-
Kyowa Kirin, Inc.RecruitingGastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaJapan
-
Baylor Research InstituteNot yet recruitingMetastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
Nikolaj Frost MDRoche Pharma AG; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...RecruitingNon-Small Cell Lung Cancer MetastaticGermany
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Lung Adenocarcinoma | Recurrent Lung Non-Small Cell Carcinoma | Recurrent Lung AdenocarcinomaUnited States
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction AdenocarcinomaChina
Clinical Trials on LC-RT-PCR and NGS
-
The University of Hong KongWithdrawn
-
Sher-E-Bangla Medical CollegeRecruitingTo Assess Long-term Effects of COVID-19 in Patients Who Were Affected With COVID -19Bangladesh
-
Port Said UniversityUnknownPositive COVID-19 by PCREgypt
-
Oswaldo Cruz FoundationNational Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust; Walter Reed Army Institute of Research (WRAIR) and other collaboratorsCompleted
-
Ambry GeneticsCrozer-Keystone Health System; St. Joseph Hospital of Orange; The Saratoga HospitalCompleted
-
Centre de l'arthrose, ParisBeaujon HospitalCompleted
-
Versailles HospitalActive, not recruitingSARS-CoV Infection | PinkeyeFrance
-
Assiut UniversityCompleted
-
Dr. Nechama SharonUnknown